FOXO4-DRI (Proxofim)

FOXO4-DRI is an experimental synthetic peptide investigated for its potential to selectively induce death in senescent cells. Its proposed relevance to age-associated tissue dysfunction rests on preclinical research rather than established benefits in humans.

Cellular senescence is a state in which cells cease dividing and can develop altered signaling activity that affects surrounding tissue. FOXO4 and p53 participate in cellular stress responses, and their interaction has been investigated as a potential contributor to senescent-cell survival.

FOXO4-DRI has been investigated as a means of interfering with the association between FOXO4 and p53. This interference is proposed to promote apoptosis in senescent cells, providing a rationale for studying senolysis rather than demonstrating reversal of biological aging.

1. 01

   Molecular target

2. 02

   Cellular signal

3. 03

   Biological process

LEVEL 02 · Preclinical research

Laboratory or animal research exists. Findings do not transfer reliably to people.

Evidence levels reflect the state of documented research only. They are not rankings of popularity, quality or suitability, and a higher level never implies that a compound is an approved medicine.

The source guide presents FOXO4-DRI as a candidate for reducing senescent-cell burden and links this concept to possible effects on aging, inflammation, tissue recovery, and neurological function. It characterizes initial animal findings as favorable regarding tolerability and mentions fatigue and discomfort as possible adverse experiences. The guide also acknowledges that human research is needed; the supplied notes do not provide study details sufficient to assess these claims independently.

Source: The Complete Guide to Peptides: Unlocking the Secrets to Health, Healing and Longevity — Hack Smith, Chapter 6, Introduction to Peptides (page references not verified)

Summarised in our own wording from the cited reference. The reference is a popular guide, not peer-reviewed literature; its statements are reported here as source claims rather than established facts.

Dosage, reconstitution and administration guidance is deliberately excluded from this platform.

Whether the proposed mechanism produces meaningful, durable benefits in humans remains unresolved. The supplied material does not establish effects on lifespan, cognition, tissue regeneration, or the selectivity of senescent-cell removal across tissues.

Safety data are limited, and the animal tolerability claims summarized by the guide do not establish human safety. The supplied notes do not substantiate the frequency or cause of the suggested adverse effects, and long-term risks remain unclear. This information is educational and is not medical advice.

Research-stage compound unless otherwise established by a competent authority. Regulatory classification differs between jurisdictions and can change over time; nothing here indicates marketing authorisation.

Primary reference for this entry:

The Complete Guide to Peptides: Unlocking the Secrets to Health, Healing and Longevity — Hack Smith, Chapter 6, Introduction to Peptides (page references not verified)

Suggested literature search terms taken from the source. They are search starting points, not citations to specific studies.

• “FOX04-DRI peptide for senolytic therapy and anti-aging”
• “FOX04-DRI in cellular rejuvenation and longevity”
• “FOX04-DRI clinical trials for tissue regeneration and”

Editorial status

source reviewed

Last updated

2026-09-14

Last reviewed

2026-09-13

Language

EN